KRASG12C Inhibitor, VRTX126 in combination with Tyrosine Kinase Inhibitor, leads to pronounced and effective response in G12C-mutated cancers. (October 2022) - Surampudi, U.K.; Bhavar, P.K.; Sarma, P.P.; Kshirsagar, A.R.; Kar, R.